Cargando...
Identification of Candidate Biomarkers for EGFR-T790M Drug-resistant Gene Mutation in Advanced Lung Adenocarcinoma
Background and objective Osimertinib is approved by Food and Drug Administration for patients with advanced non-small cell lung cancer carrying EGFR-T790M mutations. Osimertinib therapy was missed in many patients who were unable to perform biopsy due to occult lesion progression or weak body. In th...
Guardado en:
| Autores principales: | , , |
|---|---|
| Formato: | Artigo |
| Lenguaje: | Chinês |
| Publicado: |
Chinese Anti-Cancer Association; Chinese Antituberculosis Association
2020-11-01
|
| Colección: | Chinese Journal of Lung Cancer |
| Materias: | |
| Acceso en línea: | http://dx.doi.org/10.3779/j.issn.1009-3419.2020.104.20 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|